Toggle menu

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

Start date:
March 2020
Co-ordinated by:
University of Oxford
Main trial site:
Royal Infirmary of Edinburgh, Western General Hospital, St John's Hospital

Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus’ require investigation to understand pathogen biology and pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is widespread, and treatments to control potentially deleterious host responses are lacking.

The ISARIC study aims to develop a mechanistic understanding of disease processes, so that risk factors for severe illness can be identified and treatments can be developed.

When patients are confirmed to have corona virus, the research team will ask them to participate into this study. The participant will be consenting to provide blood, urine and faecal samples throughout their admission at day 1, 3 and 9, with a final follow up completed at day 28.

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Rachel O'Brien

Lead Research Nurse

Nicky Freeman

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Emily Godden

Senior Research Nurse - Renal/Acute Medicine

Nicholas Fethers

Research Administrator

Michelle Curtin

Senior Research Nurse - Stroke/Neurosurgery

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire:

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.


COVID-19 Emergency Response Assessment. A Professional Survey